

Resource Summary Report

Generated by [NIF](#) on Aug 4, 2026

Caki-2

RRID:CVCL_0235

Type: Cell Line

Proper Citation

ECACC Cat# 93120819, RRID:CVCL_0235

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0235

Proper Citation: ECACC Cat# 93120819, RRID:CVCL_0235

Description: Cell line Caki-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Papillary renal cell carcinoma

Defining Citation: [PMID:327080](#), [PMID:571047](#), [PMID:833871](#), [PMID:3518877](#), [PMID:6244232](#), [PMID:6582512](#), [PMID:6935474](#), [PMID:7459858](#), [PMID:7591954](#), [PMID:10723130](#), [PMID:10929426](#), [PMID:15585611](#), [PMID:17409424](#), [PMID:20215515](#), [PMID:22185343](#), [PMID:22460905](#), [PMID:22949125](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27993170](#), [PMID:28196595](#), [PMID:28489074](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Originally thought to be a clear cell renal cell carcinoma but shown to be from a papillary renal cell carcinoma (PubMed=17409424; PubMed=27993170)..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Caki-2

Synonyms: CAKI-2, CaKi-2, caki-2, CAKI 2, Caki 2, Caki2, CAKI2

Cross References: BTO:BTO_0006204, CLO:CLO_0002177, EFO:EFO_0002150, MCCL:MCC:0000124, CLDB:cl625, CLDB:cl626, CLDB:cl627, CLDB:cl629,

4DN:4DNSRDD5W2FZ, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:HTB-47, BCRJ:0408, BioGRID_ORCS_Cell_line:583, BioSample:SAMN01821542, BioSample:SAMN01821619, BioSample:SAMN03471873, BioSample:SAMN10988361, cancercellines:CVCL_0235, CancerTools:161904, CCRID:1101HUM-PUMC000337, Cell_Model_Passport:SIDM01546, ChEMBL-Cells:ChEMBL3308071, ChEMBL-Targets:ChEMBL613852, CLS:300140, Cosmic:687941, Cosmic:874612, Cosmic:877458, Cosmic:979706, Cosmic:982278, Cosmic:1152536, Cosmic:2520633, DepMap:ACH-000234, DSMZ:ACC-54, DSMZCellDive:ACC-54, ECACC:93120819, EGA:EGAS00001000610, ENCODE:ENCBS074UKQ, ENCODE:ENCBS461KDA, ENCODE:ENCBS611WID, ENCODE:ENCBS768KGZ, ENCODE:ENCBS787YGO, GEO:GSM374478, GEO:GSM886903, GEO:GSM887968, IARC_TP53:30022, ICLC:HTL95029, IGRhCellID:Caki2, IZSLER:BS TCL 8, KCLB:30047, LiGeA:CCLE_157, PharmacDB:Caki2_164_2019, PRIDE:PXD000335, PRIDE:PXD003105, Progenetix:CVCL_0235, PubChem_Cell_line:CVCL_0235, Wikidata:Q54808377

ID: CVCL_0235

Vendor: ECACC

Catalog Number: 93120819

Record Creation Time: 20220427T215438+0000

Record Last Update: 20260801T235344+0000

Ratings and Alerts

No rating or validation information has been found for Caki-2.

Warning: Problematic cell line: Misclassified. Originally thought to be a clear cell renal cell carcinoma but shown to be from a papillary renal cell carcinoma (PubMed=17409424; PubMed=27993170).

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-068.

Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Originally thought to be a clear cell renal cell carcinoma but shown to be from a papillary renal cell carcinoma (PubMed=17409424; PubMed=27993170)..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 276 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Schiele P, et al. (2025) CD8+ T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells. *Science advances*, 11(21), eadr9331.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. *Molecular cell*.

Jiang Q, et al. (2025) HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. *Cell*, 188(7), 1807.

Nakayama Y, et al. (2025) Prolonged exposure to axitinib alters the molecular profile of Caki-2 renal cell carcinoma cells. *Molecular and clinical oncology*, 23(5), 101.

Emanuelli A, et al. (2025) Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation. *iScience*, 28(6), 112752.

Shirole NH, et al. (2025) Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. *Cancer discovery*, 15(7), 1484.

Takai Y, et al. (2025) Ankrd1 Promotes Lamellipodia Formation and Cell Motility via Interaction with Talin-1 in Clear Cell Renal Cell Carcinoma. *International journal of molecular sciences*, 26(9).

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

An S, et al. (2023) SAMHD1-induced endosomal FAK signaling promotes human renal clear cell carcinoma metastasis by activating Rac1-mediated lamellipodia protrusion. *Experimental & molecular medicine*, 55(4), 779.

Tsuchiya H, et al. (2023) Vasopressin V1a receptor and oxytocin receptor regulate murine sperm motility differently. *Life science alliance*, 6(4).

Erwin GS, et al. (2023) Recurrent repeat expansions in human cancer genomes. *Nature*, 613(7942), 96.

Hitefield NL, et al. (2023) Differential Activation of NRF2 Signaling Pathway in Renal-Cell Carcinoma Caki Cell Lines. *Biomedicines*, 11(4).

Li HT, et al. (2023) RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer. *Cell reports*, 42(1), 112016.

Lou J, et al. (2023) Lncrna FEZf1-as1 negatively regulates ETNK1 to promote malignant progression of renal cell carcinoma. *Journal of medical biochemistry*, 42(2), 232.

Zhu M, et al. (2023) PCGF6/MAX/KDM5D facilitates MAZ/CDK4 axis expression and pRCC progression by hypomethylation of the DNA promoter. *Epigenetics & chromatin*,

16(1), 9.

Grailer J, et al. (2023) A Novel Cell-based Luciferase Reporter Platform for the Development and Characterization of T-Cell Redirecting Therapies and Vaccine Development. *Journal of immunotherapy* (Hagerstown, Md. : 1997), 46(3), 96.

Li L, et al. (2023) PUS1 is a novel biomarker for evaluating malignancy of human renal cell carcinoma. *Aging*, 15(11), 5215.

Zaccagnino A, et al. (2023) An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines. *International journal of molecular sciences*, 24(6).

Yu Z, et al. (2023) Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma. *Cancer research*, 83(5), 700.